Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRD5SP)

Drug Name
Fenretinide Drug Info
Synonyms
RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR
Cross-matching ID
PubChem CID
5288209
ChEBI ID
CHEMBL7301
CAS Number
CAS 65646-68-6
TTD Drug ID
D08JAC
INTEDE Drug ID
DR1893

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Protein processing in endoplasmic reticulum 2.56 0.00e+0 127/171 (74.27%) HSPA6;DDIT3;HERPUD1;...
Ferroptosis 2.46 0.00e+0 36/41 (87.8%) HMOX1;SLC7A11;GCLM;...
Proteasome 2.30 0.00e+0 44/46 (95.65%) PSMD2;PSMA7;PSMD14;...
TNF signaling pathway 2.06 0.00e+0 103/112 (91.96%) ATF4;VCAM1;MAPK13;...
Ribosome biogenesis in eukaryotes 2.00 0.00e+0 52/108 (48.15%) HEATR1;IMP4;LSG1;...
Mineral absorption 1.99 0.00e+0 48/60 (80%) HMOX1;MT1M;FTH1;...
IL-17 signaling pathway 1.83 1.07e-2 84/94 (89.36%) CXCL8;FOSL1;MAPK13;...
Cytokine-cytokine receptor interaction 1.82 1.07e-2 246/295 (83.39%) CXCL8;GDF15;IL15;...
Antigen processing and presentation 1.82 1.07e-2 60/78 (76.92%) HSPA6;HSPA1A;HSPA5;...
Fluid shear stress and atherosclerosis 1.80 9.62e-3 123/139 (88.49%) HMOX1;SQSTM1;ARHGEF2;...
NF-kappa B signaling pathway 1.77 1.46e-2 90/104 (86.54%) CXCL8;PLAU;VCAM1;...
Viral protein interaction with cytokine and cytokine re... 1.77 1.51e-2 84/100 (84%) CXCL8;CCL22;CXCL12;...
HIF-1 signaling pathway 1.76 1.40e-2 105/109 (96.33%) HMOX1;SLC2A1;EIF4EBP1;...
Prostate cancer 1.74 2.21e-2 93/97 (95.88%) ATF4;PLAU;NKX3-1;...
Amino sugar and nucleotide sugar metabolism 1.74 2.07e-2 38/48 (79.17%) HK2;UGDH;UAP1;...
Folate biosynthesis 1.71 2.61e-2 23/26 (88.46%) AKR1C3;AKR1B10;AKR1B1;...
Legionellosis 1.71 2.70e-2 51/57 (89.47%) CXCL8;HSPA6;HSPA1A;...
Lipid and atherosclerosis 1.70 2.61e-2 190/215 (88.37%) CXCL8;HSPA6;DDIT3;...
Longevity regulating pathway 1.67 2.98e-2 90/151 (59.6%) HSPA6;HSPA1A;EIF4EBP1;...
Toll-like receptor signaling pathway 1.66 3.74e-2 94/104 (90.38%) CXCL8;MAPK13;CTSK;...
Protein export 1.65 4.33e-2 17/23 (73.91%) HSPA5;SRPRA;SRPRB;...
Osteoclast differentiation 1.64 4.37e-2 117/127 (92.13%) SQSTM1;FOSL1;PPARG;...
Cysteine and methionine metabolism 1.64 4.32e-2 43/50 (86%) GCLM;PHGDH;PSAT1;...
Cellular senescence 1.63 4.63e-2 139/156 (89.1%) CXCL8;SQSTM1;EIF4EBP1;...
Endocrine and other factor-regulated calcium reabsorpti... -1.67 4.49e-2 49/53 (92.45%) ATP1B3;DNM3;GNAQ;...
Cardiac muscle contraction -1.71 3.26e-2 64/87 (73.56%) CACNB1;CYC1;CACNA2D1;...
Hypertrophic cardiomyopathy -1.78 2.06e-2 81/90 (90%) CACNG4;ITGB8;CACNB1;...
Pyruvate metabolism -1.79 2.09e-2 41/47 (87.23%) ACACA;ME2;PKLR;...
Diabetic cardiomyopathy -1.83 1.22e-2 162/203 (79.8%) PIK3CB;NDUFA10;NCF2;...
Valine, leucine and isoleucine degradation -1.84 1.28e-2 42/48 (87.5%) EHHADH;AOX1;HMGCL;...
Dilated cardiomyopathy -1.89 4.58e-3 86/96 (89.58%) ITGA1;LAMA2;TGFB3;...
Steroid biosynthesis -1.95 3.05e-3 19/20 (95%) FDFT1;EBP;CYP51A1;...
Terpenoid backbone biosynthesis -1.96 4.58e-3 18/22 (81.82%) GGPS1;FNTB;PDSS2;...
Oxidative phosphorylation -1.98 0.00e+0 93/133 (69.92%) ATP6V1B1;COX11;ATP6V0E1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H